Validation of a leishmania RNA virus-1 detection assay in a non-endemic setting  by Lau, R. et al.
162 16th ICID Abstracts / International Journal of Infectious Diseases 21S (2014) 1–460
Type: Poster Presentation
Final Abstract Number: 45.020
Session: Parasitology and Parasitic Infections
Date: Thursday, April 3, 2014
Time: 12:45-14:15
Room: Ballroom
Validation of a leishmania RNA virus-1
detection assay in a non-endemic setting
R. Lau1, B. Valencia2, F. Ralevski1, A.
Llanos-Cuentas3, A.K. Boggild4,∗
1 Public Health Ontario Laboratories, Toronto,
Canada
2 Institute of Tropicale Medicine “Alexander von
Humboldt”, Lima, Peru
3 Institute of Tropical Medicine “Alexander von
Humboldt”, Lima, Peru
4 Tropical Disease Unit, Division of Infectious
Diseases, University Health Network-Toronto
General Hospital, Toronto, Canada
Background: Tegumentary leishmaniasis is an emerging dis-
ease among travelers, and case reports suggest that TL among
travelersmaybeparticularly severe. LeishmaniaRNAvirus-1 (LRV1)
has been implicated in the pathogenesis of severe TL in murine
models, though whether this extends to humans is unknown. We
sought to validate a LRV-1 detection assay.
Methods & Materials: ATCC reference and clinical strains of
Leishmania identiﬁed to species level were screened for LRV1.
Two real time PCR assays for detection of LRV1 were performed
with LRV1 set A and set B primers. Ampliﬁcation of Leishmania
kinetoplastid membrane protein 11 (kmp11) served as a quan-
tiﬁcation and extraction control. ATCC L. (V.) guyanensis strain
MHOM/BR/75/M4147 was used as a positive control.
Results: We screened 5 New World ATCC strains of Leishmania
(L. amazonensis, L. mexicana, L. (V.) braziliensis, L. (V.) panamensis,
and L. (V.) guyanensis) and 12 clinical strains from primary clini-
cal samples including: bone marrow (N=1), whole blood (N=2),
skin scraping (N=2), skin biopsy (N=2), cytology brush (N=4) and
unspeciﬁed (N=1). Causative Leishmania species in clinical speci-
mens were as follows: L. chagasi/infantum (N=3), L. (V.) braziliensis
(N=3), L. tropica (N=2), L. (V.) panamensis (N=1), L. major (N=1),
and L. (V.) guyanensis (N=1). Ampliﬁcation of LRV1 primer sets A
and B along with kmp11 only occurred with the ATCC strain of L.
(V.) guyanensis known to harbour LRV1. Kmp11 alone was ampli-
ﬁed in the remaining ATCC strains, and in 6 of 12 (50%) clinical
strains, thus 80% of ATCC strains and 50% of clinical strains could
be deemed negative for LRV1. Neither LRV1 setA or B primers nor
kmp11 were ampliﬁed in 6 of 12 (50%) clinical strains, leading to
an indeterminant result regarding LRV1 co-infection status.
Conclusion: Detection of LRV1 from clinical strains of Leish-
maniamaybecome relevant to clinicians in the future. Performance
of the LRV1 assay was superior in cultured ATCC strains, which
reﬂects high parasite concentrations in culture compared to pri-
mary clinical specimens. In 50% of clinical isolates, we were able to
assign an LRV1 result, thus, further optimization of assay perfor-
mance in primary clinical specimens is warranted.
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Background: Tegumentary leishmaniasis is an emerging dis-
ease among travelers. Diagnosis of TL rests on demonstration of
parasites by culture or microscopy, both of which are insensi-
tive and operator dependent. We validated a molecular diagnostic
algorithm for Leishmania detection and species identiﬁcation using
clinical specimens.
Methods & Materials: Microscopy, culture, and Leishmania
genus 18S real time PCR were performed on clinical specimens
sent for Leishmaniadetection betweenMay2012 andOctober 2013.
Specimens positive by 18S PCR were subjected to ITS1 end-point
PCR followed by restriction fragment length polymorphism (RFLP),
which identiﬁes L. donovani, L. chagasi/infantum, L. major, L. tropica,
L. amazonensis, and L. mexicana. For the Viannia sub-genus, ampli-
ﬁcation of the ITS1 region differentiates L. (V.) braziliensis from the
other species within the complex. Species identiﬁcation was con-
ﬁrmed by Sanger sequencing of the ITS2 region or by a combination
of Mpi (mannose phosphate isomerase), Cpb (cysteine proteinase
b), andHsp70 (heat shock protein-70) PCR-RFLP/Sanger sequencing
for L. Viannia complex.
Results: Forty-ﬁve specimens from 36 individuals were tested
for Leishmania during the study period, and of these, 20 spec-
imens from 14 individuals were positive. Primary specimens
were as follows: bone marrow (N=5), organ (N=2), whole blood
(N=3), skin scraping (N=5), skin biopsy (N=10), skin aspirate
(N=9), ﬁlter paper (N=3), cytology brush (N=5) and unspeciﬁed
(N=3). Compared to 18S PCR (gold standard), culture had a sen-
sitivity of 15% and speciﬁcity of 100%, while microscopy had a
sensitivity of 27% and speciﬁcity of 100%. Among the 14 individ-
uals with conﬁrmed Leishmania infection, causative species were
as follows: L. tropica (N=3), L. (V.) panamensis (N=3), L. cha-
gasi/infantum (N=2), L. major (N=2), L. (V.) braziliensis (N=2), and
L. (V.) guyanensis (N=1). Turnaround time of 18S and ITS1 PCR is
2 days, while 18S PCR followed by PCR-RFLP or ITS2 sequencing is
4 days.
Conclusion: Using a combination of end-point and real time
PCR, along with RFLP and sequencing, we have demonstrated reli-
able detection and species identiﬁcation of Leishmania froma range
of primary clinical specimens. The utility of culture andmicroscopy
